Literature DB >> 27057447

Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer.

Fabian Echterdiek1, Jonas Janikovits1, Laura Staffa1, Meike Müller1, Bernd Lahrmann2, Monika Frühschütz1, Benjamin Hartog1, Nina Nelius1, Axel Benner3, Mirjam Tariverdian4, Magnus von Knebel Doeberitz1, Niels Grabe2, Matthias Kloor1.   

Abstract

Microsatellite instability (MSI-H) is caused by DNA mismatch repair deficiency and occurs in 15% of colorectal cancers. MSI-H cancers generate highly immunogenic frameshift peptide (FSP) antigens, which elicit pronounced local immune responses. A subset of MSI-H colorectal cancers develops in frame of Lynch syndrome, which represents an ideal human model for studying the concept of immunoediting. Immunoediting describes how continuous anti-tumoral immune surveillance of the host eventually leads to the selection of tumor cells that escape immune cell recognition and destruction. Between 30 and 40% of Lynch syndrome-associated colorectal cancers display loss of HLA class I antigen expression as a result of Beta2-microglobulin (B2M) mutations. Whether B2M mutations result from immunoediting has been unknown. To address this question, we related B2M mutation status of Lynch syndrome-associated colorectal cancer specimens (n = 30) to CD3-positive, CD8-positive and FOXP3-positive T cell infiltration in both tumor and normal mucosa. No significant correlation between B2M mutations and immune cell infiltration was observed in tumor tissue. However, FOXP3-positive T cell infiltration was significantly lower in normal mucosa adjacent to B2M-mutant (mt) compared to B2M-wild type (wt) tumors (mean: 0.98% FOXP3-positive area/region of interest (ROI) in B2M-wt vs. 0.52% FOXP3-positive area/ROI in B2M-mt, p = 0.023). Our results suggest that in the absence of immune-suppressive regulatory T cells (Treg), the outgrowth of less immunogenic B2M-mt tumor cells is favored. This finding supports the immunoediting concept in human solid cancer development and indicates a critical role of the immune milieu in normal colonic mucosa for the course of disease.

Entities:  

Keywords:  Beta2-microglobulin; Lynch syndrome; colorectal cancer; hereditary cancer; immunoediting; microsatellite instability; regulatory T cells

Year:  2015        PMID: 27057447      PMCID: PMC4801455          DOI: 10.1080/2162402X.2015.1075692

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  43 in total

1.  Genome-wide differential genetic profiling characterizes colorectal cancers with genetic instability and specific routes to HLA class I loss and immune escape.

Authors:  Mónica Bernal; Fernando García-Alcalde; Angel Concha; Carlos Cano; Armando Blanco; Federico Garrido; Francisco Ruiz-Cabello
Journal:  Cancer Immunol Immunother       Date:  2011-11-10       Impact factor: 6.968

2.  Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset.

Authors:  Heather Hampel; Julie A Stephens; Eero Pukkala; Risto Sankila; Lauri A Aaltonen; Jukka-Pekka Mecklin; Albert de la Chapelle
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

3.  Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer.

Authors:  Jonathan A D Simpson; Ahmad Al-Attar; Nicholas F S Watson; John H Scholefield; Mohammad Ilyas; Lindy G Durrant
Journal:  Gut       Date:  2010-07       Impact factor: 23.059

4.  Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens.

Authors:  M Linnebacher; J Gebert; W Rudy; S Woerner; Y P Yuan; P Bork; M von Knebel Doeberitz
Journal:  Int J Cancer       Date:  2001-07-01       Impact factor: 7.396

5.  Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers.

Authors:  Matthias Kloor; Christina Becker; Axel Benner; Stefan M Woerner; Johannes Gebert; Soldano Ferrone; Magnus von Knebel Doeberitz
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

6.  A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells.

Authors:  I Saeterdal; M K Gjertsen; P Straten; J A Eriksen; G Gaudernack
Journal:  Cancer Immunol Immunother       Date:  2001-11       Impact factor: 6.968

Review 7.  Immune infiltration in human tumors: a prognostic factor that should not be ignored.

Authors:  F Pagès; J Galon; M-C Dieu-Nosjean; E Tartour; C Sautès-Fridman; W-H Fridman
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

Review 8.  Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes.

Authors:  Monica Bernal; Francisco Ruiz-Cabello; Angel Concha; Annette Paschen; Federico Garrido
Journal:  Cancer Immunol Immunother       Date:  2012-07-26       Impact factor: 6.968

9.  Prognostic impact of β-2-microglobulin expression in colorectal cancers stratified by mismatch repair status.

Authors:  Viktor Hendrik Koelzer; Kristi Baker; Daniela Kassahn; Daniel Baumhoer; Inti Zlobec
Journal:  J Clin Pathol       Date:  2012-08-02       Impact factor: 3.411

10.  Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial.

Authors:  A Tikidzhieva; A Benner; S Michel; A Formentini; K-H Link; W Dippold; M von Knebel Doeberitz; M Kornmann; M Kloor
Journal:  Br J Cancer       Date:  2012-02-21       Impact factor: 7.640

View more
  9 in total

1.  Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas.

Authors:  Mark Clendenning; Alvin Huang; Harindra Jayasekara; Marie Lorans; Susan Preston; Neil O'Callaghan; Bernard J Pope; Finlay A Macrae; Ingrid M Winship; Roger L Milne; Graham G Giles; Dallas R English; John L Hopper; Aung K Win; Mark A Jenkins; Melissa C Southey; Christophe Rosty; Daniel D Buchanan
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

2.  Leveraging premalignant biology for immune-based cancer prevention.

Authors:  Avrum Spira; Mary L Disis; John T Schiller; Eduardo Vilar; Timothy R Rebbeck; Rafael Bejar; Trey Ideker; Janine Arts; Matthew B Yurgelun; Jill P Mesirov; Anjana Rao; Judy Garber; Elizabeth M Jaffee; Scott M Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-16       Impact factor: 11.205

3.  Precancer Atlas to Drive Precision Prevention Trials.

Authors:  Avrum Spira; Matthew B Yurgelun; Ludmil Alexandrov; Anjana Rao; Rafael Bejar; Kornelia Polyak; Marios Giannakis; Ali Shilatifard; Olivera J Finn; Madhav Dhodapkar; Neil E Kay; Esteban Braggio; Eduardo Vilar; Sarah A Mazzilli; Timothy R Rebbeck; Judy E Garber; Victor E Velculescu; Mary L Disis; Douglas C Wallace; Scott M Lippman
Journal:  Cancer Res       Date:  2017-04-01       Impact factor: 13.312

4.  Immunoprofiles of colorectal cancer from Lynch syndrome.

Authors:  Joanna Walkowska; Thomas Kallemose; Göran Jönsson; Mats Jönsson; Ove Andersen; Mads Hald Andersen; Inge Marie Svane; Anne Langkilde; Mef Nilbert; Christina Therkildsen
Journal:  Oncoimmunology       Date:  2018-09-26       Impact factor: 8.110

5.  High endothelial venules are associated with microsatellite instability, hereditary background and immune evasion in colorectal cancer.

Authors:  Pauline L Pfuderer; Alexej Ballhausen; Florian Seidler; Hans-Jürgen Stark; Niels Grabe; Ian M Frayling; Ann Ager; Magnus von Knebel Doeberitz; Matthias Kloor; Aysel Ahadova
Journal:  Br J Cancer       Date:  2019-07-30       Impact factor: 7.640

6.  The mutational profile and infiltration pattern of murine MLH1-/- tumors: concurrences, disparities and cell line establishment for functional analysis.

Authors:  Claudia Maletzki; Franziska Beyrich; Maja Hühns; Ernst Klar; Michael Linnebacher
Journal:  Oncotarget       Date:  2016-08-16

7.  Complex pattern of immune evasion in MSI colorectal cancer.

Authors:  Mine Ozcan; Jonas Janikovits; Magnus von Knebel Doeberitz; Matthias Kloor
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

Review 8.  Challenges of Neoantigen Targeting in Lynch Syndrome and Constitutional Mismatch Repair Deficiency Syndrome.

Authors:  Asima Abidi; Mark A J Gorris; Evan Brennan; Marjolijn C J Jongmans; Dilys D Weijers; Roland P Kuiper; Richarda M de Voer; Nicoline Hoogerbrugge; Gerty Schreibelt; I Jolanda M de Vries
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

Review 9.  Immunology of Lynch Syndrome.

Authors:  Danielle M Pastor; Jeffrey Schlom
Journal:  Curr Oncol Rep       Date:  2021-06-14       Impact factor: 5.075

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.